Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine - PubMed (original) (raw)
Comparative Study
. 2001 Dec;82(Pt 12):2881-2888.
doi: 10.1099/0022-1317-82-12-2881.
Affiliations
- PMID: 11714962
- DOI: 10.1099/0022-1317-82-12-2881
Comparative Study
Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine
Gregory A Prince et al. J Gen Virol. 2001 Dec.
Abstract
A formalin-inactivated respiratory syncytial virus vaccine was used to immunize infants in the mid-1960s; when these children later were naturally infected by the virus they developed markedly accentuated disease, and two died. For the present work, a new batch of vaccine was prepared using the original formula. Administration of either the old or new vaccines resulted in enhanced lesions in immunized cotton rats subsequently challenged with live virus, although administration of the vaccine reduced virus replication by 90%. Animals primed with formalin-inactivated virus and challenged developed markedly accentuated lesions of the same type as in animals undergoing primary or secondary infection. In addition, the animals with the vaccine-enhanced disease developed alveolitis and interstitial pneumonitis, which appear to be specific markers for the vaccine enhancement. The newly prepared vaccine appears suitable as a reference standard for studying the mechanism of vaccine-enhanced disease caused by this virus. Additionally, we reviewed the lesions in the lungs of the two humans who died with the vaccine-enhanced disease in 1967, and found that they were similar to, but more severe than those seen in the cotton rats.
Similar articles
- Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon.
Piedra PA, Wyde PR, Castleman WL, Ambrose MW, Jewell AM, Speelman DJ, Hildreth SW. Piedra PA, et al. Vaccine. 1993 Nov;11(14):1415-23. doi: 10.1016/0264-410x(93)90170-3. Vaccine. 1993. PMID: 7508665 - Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease.
Prince GA, Denamur F, Deschamps M, Garçon N, Prieels JP, Slaoui M, Thiriart C, Porter DD. Prince GA, et al. Vaccine. 2001 Feb 28;19(15-16):2048-54. doi: 10.1016/s0264-410x(00)00417-5. Vaccine. 2001. PMID: 11228376 - Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus.
Boukhvalova MS, Yim KC, Blanco J. Boukhvalova MS, et al. Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618770518. doi: 10.1177/2040206618770518. Antivir Chem Chemother. 2018. PMID: 29768937 Free PMC article. Review. - Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease.
Delgado MF, Polack FP. Delgado MF, et al. Expert Rev Vaccines. 2004 Dec;3(6):693-700. doi: 10.1586/14760584.3.6.693. Expert Rev Vaccines. 2004. PMID: 15606354 Review.
Cited by
- Design of hepadnavirus core protein-based chimeric virus-like particles carrying epitopes from respiratory syncytial virus.
Shao S, Zhang XF, Hou JW, Yang SS, Han ZB, Wu HL, Tang F, Li XY, Lei ZH, Zhao ZX, Li SX, Liu ZM, Shan P, Jin YQ, Su JG, Liang Y, Zhang J, Li QM. Shao S, et al. NPJ Vaccines. 2024 Mar 19;9(1):62. doi: 10.1038/s41541-024-00855-7. NPJ Vaccines. 2024. PMID: 38503757 Free PMC article. - Ally, adversary, or arbitrator? The context-dependent role of eosinophils in vaccination for respiratory viruses and subsequent breakthrough infections.
Chang LA, Schotsaert M. Chang LA, et al. J Leukoc Biol. 2024 Jul 25;116(2):224-243. doi: 10.1093/jleuko/qiae010. J Leukoc Biol. 2024. PMID: 38289826 Free PMC article. Review. - Cationic-nanogel nasal vaccine containing the ectodomain of RSV-small hydrophobic protein induces protective immunity in rodents.
Umemoto S, Nakahashi-Ouchida R, Yuki Y, Kurokawa S, Machita T, Uchida Y, Mori H, Yamanoue T, Shibata T, Sawada SI, Ishige K, Hirano T, Fujihashi K, Akiyoshi K, Kurashima Y, Tokuhara D, Ernst PB, Suzuki M, Kiyono H. Umemoto S, et al. NPJ Vaccines. 2023 Jul 24;8(1):106. doi: 10.1038/s41541-023-00700-3. NPJ Vaccines. 2023. PMID: 37488116 Free PMC article. - Eosinophils as potential biomarkers in respiratory viral infections.
Macchia I, La Sorsa V, Urbani F, Moretti S, Antonucci C, Afferni C, Schiavoni G. Macchia I, et al. Front Immunol. 2023 Jul 6;14:1170035. doi: 10.3389/fimmu.2023.1170035. eCollection 2023. Front Immunol. 2023. PMID: 37483591 Free PMC article. Review. - Gamma Irradiation-Inactivated Respiratory Syncytial Virus Vaccine Provides Protection but Exacerbates Pulmonary Inflammation by Switching from Prefusion to Postfusion F Protein.
Chen F, Park HR, Ji HJ, Kwon Y, Kim MK, Song JY, Ahn KB, Seo HS. Chen F, et al. Microbiol Spectr. 2023 Aug 17;11(4):e0135823. doi: 10.1128/spectrum.01358-23. Epub 2023 Jun 5. Microbiol Spectr. 2023. PMID: 37272801 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical